Prelude Therapeutics Inc (PRLD) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-10

Prelude Therapeutics Inc (PRLD) has filed 11 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-10. 4 Form 8-K material event filings were reported by PRLD in the last 90 days. InsiderAlpha tracks every PRLD SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Prelude Therapeutics Inc (PRLD)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001678660

90-Day SEC Filing Activity

Form 4 filings (90d)	11
Form 8-K filings (90d)	4
Latest Form 4 filing	2026-06-10

Recent PRLD Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-04-27	RA CAPITAL MANAGEMENT, L.P.	Insider	J — Other acquisition / disposition	1.41M	—	—	SEC
2026-04-21	Bonita David P	Director	P — Open-market purchase	1.13M	$4.44	$5.00M	SEC
2026-04-21	Bonita David P	Director	P — Open-market purchase	1.69M	$4.44	$7.50M	SEC
2026-04-21	ORBIMED ADVISORS LLC	Director	P — Open-market purchase	1.13M	$4.44	$5.00M	SEC
2026-04-21	ORBIMED ADVISORS LLC	Director	P — Open-market purchase	1.69M	$4.44	$7.50M	SEC
2025-10-04	Huang Jane	President, CMO	M — Option exercise	9.4K	—	—	SEC
2025-10-04	Huang Jane	President, CMO	F — Tax withholding / forfeiture	3.4K	$1.47	$5K	SEC
2025-07-04	Huang Jane	President, CMO	F — Tax withholding / forfeiture	3.4K	$0.79	$3K	SEC
2025-07-04	Huang Jane	President, CMO	M — Option exercise	9.4K	—	—	SEC
2024-12-23	Combs Andrew	Chief Chemistry Officer	P — Open-market purchase	60.0K	$1.37	$82K	SEC
2024-12-20	Combs Andrew	Chief Chemistry Officer	P — Open-market purchase	3.1K	$1.15	$4K	SEC
2024-12-19	Lim Bryant David	CLO, Interim CFO, Corp Sec.	P — Open-market purchase	25.0K	$0.91	$23K	SEC
2024-12-19	Vaddi Krishna	CEO	P — Open-market purchase	6.9K	$0.89	$6K	SEC
2024-12-18	Vaddi Krishna	CEO	P — Open-market purchase	100.0K	$0.93	$93K	SEC
2024-10-04	Huang Jane	President, CMO	M — Option exercise	9.4K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Prelude Therapeutics Inc (PRLD). Updated in real time as new filings are submitted to the SEC.

Most-Active PRLD Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
BAKER BROS. ADVISORS LP	4	$10.00M
Bonita David P	3	$12.50M
RA CAPITAL MANAGEMENT, L.P.	2	—
ORBIMED ADVISORS LLC	2	$12.50M
Sandor Victor	1	—

Recent PRLD Form 8-K Material Events

2026-06-10 — Item 5.07 [SEC]
2026-05-12 — Item 2.02, 7.01, 9.01 [SEC]
2026-04-20 — Item 1.01, 8.01, 9.01 · Financing · neutral [SEC]
Prelude Therapeutics entered into an underwriting agreement to issue 18.0 million shares of common stock at $4.44 per share and 2.3 million pre-funded warrants, raising approximately $85.5 million in net proceeds. The company intends to use the proceeds for general corporate purp
2026-04-20 — Item 7.01, 8.01, 9.01 · Clinical · positive [SEC]
Prelude Therapeutics announced the presentation of preclinical data for its lead candidate PRT13722, a first-in-class, orally bioavailable KAT6A degrader, at the AACR Annual Meeting 2026 on April 20, 2026. The preclinical data demonstrates robust efficacy in HR+/HER2- breast canc
2026-04-15 — Item 5.02, 9.01 · Leadership · neutral [SEC]
Prelude Therapeutics appointed Charles Q. Morris, M.D. as Chief Medical Officer effective April 20, 2026. Dr. Morris brings extensive experience as CMO at multiple biotech companies including Lava Therapeutics, Celyad Oncology, and Radius Health, and will receive a base salary of

Recent Insider Filings

2026-06-10 — BAKER BROS. ADVISORS LP (Insider)
2026-06-10 — Dorton Katina (Insider)
2026-06-10 — Babler Martin (Insider)
2026-06-10 — Bonita David P (Insider)
2026-06-10 — Sandor Victor (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in PRLD insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

PRLD Insider Trading — FAQ

What is the latest insider trade for PRLD?: Prelude Therapeutics Inc (PRLD) had 11 insider filings in the last 90 days, with the most recent on 2026-06-10. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying PRLD stock?: 0 insider purchases of PRLD were filed in the last 90 days.
How many insiders are selling PRLD stock?: 0 insider sales of PRLD were filed in the last 90 days.
Where can I see PRLD SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every PRLD SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live PRLD dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.